PHOTOCREO Michal Bednarek / Shutterstock.com
US Congress must exempt biopharmaceutical patents from PTAB review to ensure continued medical innovation, argues Peter Pitts of the Center for Medicine in the Public Interest.
The UK’s pharmaceutical industry reportedly employs more than 70,000 workers and in 2013 contributed around £13 billion ($20.2 billion) to the economy.
The industry’s future, however, could be in jeopardy due to patent law changes across the Atlantic. British drug firms’ intellectual property faces an unprecedented threat from a US patent review board. The Patent Trial and Appeal Board (PTAB) has invalidated many legitimate patents.
In 2011, Congress passed the American Invents Act (AIA), which established the PTAB. Lawmakers hoped the PTAB would efficiently resolve disputes between patent owners and alleged infringers that challenge the legitimacy of certain patents. Congress gave the PTAB the power to invalidate the overly broad patents used by ‘patent trolls’.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
PTAB, AIA, patent, biopharma, Peter Pitts, Center for Medcine in the Public Interest,
